Bone Marrow Failure Syndromes
Optimizing Outcomes
Worldwide through
Disease Understanding
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: February 28, 2009
Expiration Date: February 28, 2011
Estimated Time of Completion: 3 hours
Description
Bone Marrow Failure Syndromes: Optimizing Outcomes Worldwide through Disease Understanding Webcast Series was filmed in front of a live audience during a satellite symposium at the ASH Annual Meeting. The goal of this series is to review the pathobiology of these disorders, describe the variations in disease patterns across global regions, and evaluate the rationale for therapies and their evidence-based, clinically relevant application.
Objectives
At the conclusion of this activity, the participant will be able to do the following:
- Distinguish variations in bone marrow failure epidemiology and treatment approaches in different regions of the world;
- Describe the molecular basis of bone marrow failure syndromes, including array-based disease characteristics;
- Develop treatment strategies that target epigenetic and other pathobiologic bases for bone marrow failure disorders;
- Formulate strategies to minimize transformation of bone marrow failure syndromes to acute myeloid leukemia;
- Apply knowledge of treatment approaches for bone marrow failure syndrome to clinical practice;
- Identify practical strategies to make clinical trial involvement available to patients.
Target Audience
This educational activity is designed for medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied healthcare professionals treating patients with hematologic malignancies. In addition, members of patient advocacy groups will benefit from this program.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing medical
education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director| Mikkael Sekeres, MD, MS Associate Professor of Medicine Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio |
| Louis DeGennaro, PhD Chief Scientific Officer Leukemia and Lymphoma Society White Plains, New York |
James G. Herman, MD Associate Professor The Johns Hopkins University School of Medicine Baltimore, Maryland |
| Pierre Fenaux, MD, PhD Professor of Hematology Avicenne Hospital/University of Paris Bobigny, France |
Alice Houk, MS Director, Health Professional Programs Aplastic Anemia & Myelodysplastic Syndromes International Foundation, Inc Churchton, Maryland |
| Aristoteles A.N. Giagounidis, MD, PhD Associate Professor of Medicine St. Johannes Hospital Duisburg, Germany |
Jaroslaw P. Maciejewski, MD, PhD Chief, Hematopoieses & Experimental Hematology Section Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation
Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation
Center for Continuing Education requires resolution of all faculty conflicts of interest to
ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
| Pierre Fenaux, MD, PhD | |||
| Membership on advisory committee/review panels: |
Amgen; Celgene Corporation; Cephalon; Janssen-Cilag; Novartis; Pharmion Corporation; Roche | ||
| Aristoteles A.N. Giagounidis, MD, PhD | |||
| Consulting: | Celgene Corporation; Novartis; Ortho Biotech; Pharmion Corporation | ||
| Teaching and Speaking: | Novartis; Pharmion Corporation; Roche | ||
| Stock Owner: | Pfizer, Inc. | ||
| James G. Herman, MD | |||
| Consulting: | OncoMethylome Sciences; Pharmion Corporation | ||
| Intellectual Property Rights: | OncoMethylome Sciences | ||
| Jaroslaw P. Maciejewski, MD, PhD | |||
| Membership on advisory committee/review panels: |
Celgene Corporation
|
||
| Mikkael Sekeres, MD, MS | |||
| Consulting: | Pharmion Corporation | ||
| Teaching and Speaking: | Celgene Corporation | ||
| Research: | Celgene Corporation | ||
The following faculty has indicated he/she has no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Louis DeGennaro, PhD
Alice Houk, MS
The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of this activity from:
Celgene Corporation
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and UNITECH Communications®.
